Table 2.
Changes in knee-joint functions and locomotor functions in subjects eligible for efficacy assessmenta
| Variables | Values at each time pointb
|
Two-way ANOVA (group × time) P-value | ||||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | ||
| JKOM | ||||||
| (I) VAS score for knee pain (mm) | ||||||
| GCQID | 27.0±3.4 | 24.2±3.1 | 17.1±2.5* | 14.0±3.0** | 9.8±2.3** | 0.939 |
| Placebo | 28.5±3.0 | 24.2±3.3 | 18.7±3.2* | 13.0±2.5** | 11.4±2.1** | |
| (II–V) Total score (points) | ||||||
| GCQID | 14.0±1.6 | 11.8±1.5 | 9.2±1.0* | 9.1±1.2** | 8.5±1.1** | 0.362 |
| Placebo | 13.0±1.0 | 12.6±1.1 | 11.0±1.1 | 10.5±1.2 | 9.3±0.9* | |
| VAS score for pain on walking (mm) | ||||||
| GCQID | 23.7±3.3 | 16.2±2.8 | 12.5±2.5** | 9.6±2.3** | 7.1±2.2** | 0.216 |
| Placebo | 18.6±2.2 | 16.1±2.9 | 15.0±3.1 | 11.6±2.3* | 7.3±1.6** | |
| Normal walking speed (m/s) | ||||||
| GCQID | 1.28±0.03 | 1.32±0.03* | 1.35±0.02** | 0.524 | ||
| Placebo | 1.28±0.02 | 1.32±0.02* | 1.33±0.02** | |||
| Knee-extensor strength (% body weight)c | ||||||
| GCQID | 95.9±5.0 | 104.6±5.0* | 104.5±4.9* | 0.546 | ||
| Placebo | 88.1±5.8 | 92.3±5.5 | 92.6±5.6 | |||
Notes:
a
GCQID group (n=41) and placebo group (n=41).
b
Values expressed as mean ± standard error.
c
Knee-extensor strength was measured in both knees and expressed as the total strength of both knees.
*
P<0.05 and
**
P<0.01 compared with baseline value.
Abbreviations: ANOVA, analysis of variance; GCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, and vitamin D; JKOM, Japanese Knee Osteoarthritis Measure; VAS, visual analog scale.